Contains Nonbinding Recommendations

**Draft Guidance on Rivastigmine**

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Rivastigmine

**Form/Route:** Film, Extended Release/Transdermal

**Recommended studies:** 2 studies

1. **Type of study:** Bioequivalence (BE) with Pharmacokinetic (PK) Endpoints Study  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 9.5 mg/24 hr  
   **Subjects:** Healthy males and nonpregnant females, general population.  
   **Additional comments:** The transdermal patch should be applied to clean, dry, hairless, intact healthy skin on the upper back, chest, or upper arm, as recommended in the approved reference listed drug (RLD) labeling and worn for 24 hours.

2. **Type of study:** Skin Irritation, Sensitization, and Adhesion Study  
   **Design:** Randomized, evaluator-blinded, in vivo within-subject repeat test  
   **Strength:** 4.6 mg/24 hr  
   **Subjects:** Healthy males and nonpregnant females, general population.  
   **Additional comments:** Specific recommendations are provided below.

**Analytes to measure (in appropriate biological fluid):** Rivastigmine in plasma (PK study only)

**Bioequivalence based on (90% CI):** Rivastigmine (PK study only)

**Waiver request of in vivo PK testing:** 4.6 mg/24 hr based on (i) acceptable bioequivalence study on the 9.5 mg/24 hr strength, (ii) proportional similarity across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

**Dissolution test method and sampling times:**

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

In addition to the method above, dissolution profiles on 12 dosage units each of all strengths of the test and reference products generated using at least three dissolution media (pH 1.2, 4.5, 6.8 buffer) and water should be submitted in the application. Agitation speeds may have to be increased, if appropriate. It is acceptable to add a small amount of surfactant, if necessary. Please include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.

**Recommended Aug 2009**
Additional comments regarding the skin irritation, sensitization and adhesion study:

1. The Office of Generic Drugs (OGD) recommends evaluating skin irritation, sensitization, and adhesion in the same study. To support approval, the test product must be no more irritating than the RLD, be no more sensitizing than the RLD and adhere at least as well as the RLD. Each parameter is to be evaluated with a separate analysis. The primary endpoints should be considered as co-primary endpoints, e.g., for each of them, the study must demonstrate that the test product is no worse than the RLD. The analysis for each parameter and the primary endpoint(s) and any secondary endpoint(s) for each analysis are to be clearly defined in the protocol prior to the start of the study. A clear, objective definition of a sensitization reaction is also to be prespecified in the protocol.

2. The recommended study consists of two phases, a 21-day Induction Phase, followed by a 14 to 17 day rest period, and a Challenge Phase.

   During the Induction Phase, all test articles (i.e., 4.6 mg/24 hr test product\(^1\), 4.6 mg/24 hr RLD, optional vehicle patch\(^2\) and optional negative control\(^3\)) are to be applied simultaneously to each subject at different sites, with sequential patch applications to the same skin sites every 24 hours (the intended duration of wear) for a total of 21 consecutive days. The patches should be applied to clean, dry, hairless, intact healthy skin on the upper back, chest, or upper arm, as recommended in the approved reference listed drug (RLD) labeling. Thus, it is recommended to apply the patches daily on Days 1-21 to the same sites and to have each of them remain in place for 1 day (a total of 21 days altogether). The Day 21 patches would be removed on Day 22. The irritation evaluation is to be conducted during the Induction Phase, with assessment of “Dermal Response” and “Other Effects” at the time of each patch change.

   The Challenge Phase consists of a single 48-hour application of the 4.6 mg/24 hr test product, 4.6 mg/24 hr RLD, optional vehicle patch and optional negative control to a naïve site followed by an assessment of “Dermal Response” and “Other Effects” at 30 minutes and at 24, 48, and 72 hours after challenge patch removal, with a narrative description of any reactions observed, together with the opinion of the investigator as to whether such reactions are felt to be indicative of a contact sensitization. A re-challenge test four to eight weeks following the original challenge, conducted in the same manner, is recommended for all subjects with a potential sensitization reaction.

3. An adequate number of subjects should be enrolled to ensure that at least 200 evaluable subjects are included in the PP population.

4. The irritation and adhesive properties may be sensitive to climate conditions. Therefore, the OGD prefers that the study be conducted in multiple centers with different climate conditions.

5. Subjects should not apply make-up, creams, lotions, powders, or other topical products to the skin area where the patch will be placed, as this could affect adhesive performance or irritation potential.

---

\(^1\) The test product evaluated should be the actual patches to be marketed.

\(^2\) The optional vehicle patch should have all of the inactive ingredients and be identical to the test product in every manner except for the absence of rivastigmine.

\(^3\) An example of the optional negative control is an occlusion type device with normal saline applied on a polyester pad within the device chamber.
6. Assignment of the test product, RLD, optional vehicle patch, and optional negative control to skin sites should be randomized. The method of randomization should be described in the protocol. It is recommended that an independent third party generate and hold the randomization code throughout the conduct of the study in order to minimize bias. A sealed copy of the randomization scheme should be retained at the study site and should be available to FDA investigators at the time of site inspection to allow for verification of the treatment identity for each application site on each subject.

7. Please refer to 21 CFR 320.38, 320.63 and the Guidance for Industry, “Handling and Retention of BA and BE Testing Samples”, regarding retention of study drug samples and 21 CFR 320.36 for requirements for maintenance of records of bioequivalence testing. In addition, the investigators should follow the procedures of 21 CFR 58 and ICH E6, “Good Clinical Practice: Consolidated Guideline”, for retention of study records and data in order to conduct their studies in compliance with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). Retention samples should be randomly selected by each drug site prior to dispensing to subjects. Retention samples should not be returned to the sponsor at any time.

8. Inclusion Criteria (the sponsor may add additional criteria):
   a. Healthy male and female subjects 18-65 years of age inclusive.
   b. Subject has a normal screening ECG; non-specific ST-T wave changes are acceptable.

9. Exclusion Criteria (the sponsor may add additional criteria):
   a. Subject is pregnant or lactating.
   b. Clinically relevant findings in screening 12-lead ECG, such as second- or third-degree atroventricular block or complete bundle branch block.
   c. Systolic blood pressure < 90 or >160 mmHg at screening measured in supine position after 5 minutes rest; diastolic blood pressure <50 or >95 mmHg at screening measured in supine position after 5 minutes rest; heart rate <50 or >100 at screening.
   d. Medical history of sick sinus syndrome, conduction defects (sinoatrial block, atroventricular block), gastroduodenal ulcerative conditions, asthma or chronic obstructive pulmonary disease, urinary obstruction, extrapyramidal symptoms such as tremor or seizures.
   e. Medical history of condition that would significantly influence the immune response (e.g., primary or acquired immunodeficiencies such as human immunodeficiency virus (HIV) positive or AIDS, allergic diseases such as anaphylaxis, asthma or generalized drug reaction, neoplasms such as lymphoma or leukemia, rheumatoid arthritis or systemic lupus erythematosus).
   f. Medical history of significant dermatologic diseases or conditions, such as atopy, psoriasis, vitiligo or conditions known to alter skin appearance or physiologic response (e.g. diabetes, porphyria).
   g. History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma), except basal cell carcinomas that were superficial and did not involve the investigative site.
   h. Within 3 weeks prior to dosing, use of cholinergic compounds.
   i. Within 3 weeks prior to dosing, use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product (e.g., cyclosporine, tacrolimus, systemic or topical corticosteroids, cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin (BCG), monoclonal antibodies, radiation therapy).
   j. Within 72 hours prior to dosing, use of antihistamines or use of topical drugs at patch site.
   k. Subject has an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at the application sites, scar tissue, tattoo, or coloration that would interfere with placement of test articles, skin assessment, or reactions to drug.
1. Presence of open sores at the application site.

10. Provide a listing of the prescription and over-the-counter drug products that are contraindicated during the study, such as:
   a. Nonsteroidal anti-inflammatory drugs (NSAIDs)
   b. Other cholinomimetic drugs
   c. Anticholinergic medications
   d. Succinylcholine-type muscle relaxants during anesthesia
   e. Use of medications or treatments that would significantly influence or exaggerate responses to the test product or that would alter inflammatory or immune response to the product (e.g. antihistamines, systemic or topical corticosteroids, cyclosporine, tacrolimus, cytotoxic drugs, immune globulin, Bacillus Calmette-Guerin (BCG), monoclonal antibodies, radiation therapy).

11. Subjects should be advised to avoid exposing the patch application site to external sources of direct heat, such as heating pads or electric blankets, heat lamps, saunas, hot tubs, heated water beds, and prolonged direct sunlight.

12. Subjects should be advised that if they need to have surgery during the study, they should inform their doctor that the rivastigmine transdermal patch may exaggerate the effects of some muscle relaxants during anesthesia.

13. Subjects should be advised that the rivastigmine transdermal patch may cause dizziness and drowsiness, mainly at the start of treatment or when increasing the dose. Subjects should be advised that if they feel dizzy or drowsy, they should not drive, use machines or perform any other tasks that require attention.

14. During the induction phase, subjects should return for daily visits on Days 1-21 for adhesion scoring, patch removal, irritation scoring, and patch replacement and on Day 22 for adhesion scoring, patch removal and irritation scoring. After wearing the challenge patch for 48 hours (or until removal due to intolerable reaction), subjects should return for adhesion scoring, patch removal and irritation scoring at 30 minutes and at 24, 48, and 72 hours after challenge patch removal. Scoring of patch adherence and skin reactions should be performed by a trained and blinded observer at each patch removal. All efforts should be made to ensure that the same scorer is used for all observations. If the same scorer is not used in all cases, inter-scorer variability needs to be addressed in the protocol, specifying the training and standards for each score.

15. Due to likely differences in appearance of the patches, blinding of the observer/evaluator may not be possible, especially for evaluation of patch adhesion, which requires direct observation of the patch itself. However, efforts should be made to blind the evaluation of irritation and sensitization.

16. To ensure adequate adhesion of the test and reference patches in the study, adhesion scores are to be recorded just prior to patch removal. The recommended scoring system for adhesion of transdermal patches is the following:

   0 = ≥ 90% adhered (essentially no liftoff the skin)
   1 = ≥ 75% to < 90% adhered (some edges only lifting off the skin)
   2 = ≥ 50% to < 75% adhered (less than half of the patch lifting off the skin)
   3 = > 0% to < 50% adhered but not detached (more than half of the patch lifting off the skin without falling off)
4 = 0% adhered - patch detached (patch completely off the skin)

17. During both the Induction Phase and Challenge Phase, the skin reactions are to be evaluated and scored according to the following two scales:\(^4\):

**Scale 1: Dermal Response**

<table>
<thead>
<tr>
<th>Skin Appearance</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No evidence of irritation</td>
<td>0</td>
</tr>
<tr>
<td>Minimal erythema, barely perceptible</td>
<td>1</td>
</tr>
<tr>
<td>Definite erythema, readily visible; or minimal edema; or minimal papular response</td>
<td>2</td>
</tr>
<tr>
<td>Erythema and papules</td>
<td>3</td>
</tr>
<tr>
<td>Definite edema</td>
<td>4</td>
</tr>
<tr>
<td>Erythema, edema, and papules</td>
<td>5</td>
</tr>
<tr>
<td>Vesicular eruption</td>
<td>6</td>
</tr>
<tr>
<td>Strong reaction spreading beyond test (i.e., application) site</td>
<td>7</td>
</tr>
</tbody>
</table>

**Scale 2: Other Effects**

<table>
<thead>
<tr>
<th>Observation</th>
<th>Score (Numeric equivalent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slightly glazed appearance</td>
<td>A (0)</td>
</tr>
<tr>
<td>Marked glazed appearance</td>
<td>B (1)</td>
</tr>
<tr>
<td>Glazing with peeling and cracking</td>
<td>C (2)</td>
</tr>
<tr>
<td>Glazing with fissures</td>
<td>F (3)</td>
</tr>
<tr>
<td>Film of dried serous exudates covering all or part of the patch site</td>
<td>G (3)</td>
</tr>
<tr>
<td>Small petechial erosions and/or scabs</td>
<td>H (3)</td>
</tr>
</tbody>
</table>

When an “Other Effects” score is observed, each score should be reported as a number and letter combination score and also as a numerical total (i.e., numerical “Dermal Response” score + numeric equivalent for the “Other Effects” lettered score).

18. For subjects who experience irritation consistent with a combined score of ≥ 3, or who experience symptomatic intolerable irritation, the patch may be moved to a new site in order to complete the 21-day Induction Phase and continue with the sensitization part of the study. In this circumstance the highest score observed (not truncated to 3) prior to discontinuation of the first patch site should be carried forward for all remaining observations in the irritation analysis.

19. After the first application, the adhesion performance of subsequent same site applications could be affected by skin stripping or residual adhesive. Therefore, formally evaluate and compare the adhesion performance of only the first applied test product and RLD. No patch reinforcement is allowed when the study is being used to establish adequate adhesion performance to support product approval; thus, no patch reinforcement should be permitted for the first applied test product and RLD patches. Adhesion should also be evaluated prior to patch removal throughout the entire study period to ensure adequate skin contact for maximal induction of irritation and sensitization. Daily adhesion evaluations are recommended.


Recommended Aug 2009
20. Criteria may be established for using tape or an overlay to reinforce any patches (after the first application) that are lifting. This may be preferable to replacing detached patches, since shorter application intervals could give different irritation results. If the patch is reinforced with tape or an overlay, skin irritation associated with the tape or overlay area should be reported separately from that of the patch application area.

21. If a patch completely detaches, it should be replaced within 24 hours and the subject should continue in the study. During the 21-day Induction Phase, if a patch is completely detached for more than 24 hours (unless the patch was removed for an unacceptable degree of irritation), the subject should be excluded from both the irritation and sensitization analyses for that product. During the 48-hr Challenge Phase, if a patch is completely detached for more than 24 hours, the subject should be excluded from the sensitization analysis. The subject should note the date and time of detachment as soon as it occurs.

Safety Data and Analyses

22. All application site reactions are to be reported in the data tables and in the detailed narrative description for each subject’s response in both phases of this study in the study report. These would include patient complaints such as dryness, itching, burning, pain, or soreness, etc., identifying to which application site the complaint applies. These reports are to be compared between test articles.

23. The safety analyses should include all patients who received a dose of study medication. Safety analyses should include comparing the test product, RLD, optional vehicle patch, and optional negative control with regard to the occurrence and severity of application site adverse events (AEs). Systemic drug-related AEs, change from baseline in blood pressure, and concomitant medications are also to be reported but cannot be distinguished between test articles.

Skin Irritation Data Tables and Analyses

24. For each day during the Induction Phase, when the skin is evaluated for irritation, please provide a frequency table showing the number of applications of each test article with each combined “Dermal Response” and “Other Effect” score using Last–Observation-Carried-Forward for subjects who discontinued a test article because of unacceptable irritation. Please refer to Table 1 as an example.

Table 1: Number (%) of Applications by Induction Phase Day and Test Article with a Specific Combined “Dermal Response” and “Other Effect” Score

<table>
<thead>
<tr>
<th>Induction Phase Scoring Day; Test Article</th>
<th>Combined “Dermal Response” and “Other Effect” Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Day 2; Test Product</td>
<td></td>
</tr>
<tr>
<td>Day 2; RLD</td>
<td></td>
</tr>
<tr>
<td>Day 2; Vehicle Patch (optional)</td>
<td></td>
</tr>
<tr>
<td>Day 2; Negative Control (optional)</td>
<td></td>
</tr>
<tr>
<td>Day 3; Test Product</td>
<td></td>
</tr>
<tr>
<td>Day 3; RLD</td>
<td></td>
</tr>
<tr>
<td>etc.</td>
<td></td>
</tr>
</tbody>
</table>

25. The Analysis Populations should be defined separately for each parameter and should be defined per patch instead of per subject. The Per Protocol (PP) Population for evaluation of skin irritation should be defined as follows:
Irritation Analysis— the test articles need to be applied sequentially to the same site for the entire 21 day induction phase (without any period of detachment longer than 24 hours) to be evaluated for the cumulative irritation effect OR if a patch is moved or removed due to excessive irritation, it should be included using Last-Observation-Carried-Forward (LOCF).

26. For each test article (4.6 mg/24 hr test product, 4.6 mg/24 hr RLD, optional vehicle patch and optional negative control), the mean cumulative irritation score is to be calculated as the sum of all combined “Dermal Response” and “Other Effects” scores observed at each observation divided by the total number of observations.

27. In addition to the cumulative irritation scores, the following data should be provided for each test article:
   a. Total number of observations with a combined “Dermal Response” and “Other Effects” irritation score of 3 or more for each product.
   b. Number of patches that were moved or removed due to an unacceptable degree of irritation.
   c. Number of days until sufficient irritation occurred to preclude repeat application to the same site.

28. To demonstrate non-inferiority of the test product compared to the RLD with regard to the cumulative irritation scores, the upper bound of the one-sided 95% CI of the mean test product score minus 1.25 times the mean RLD score must be less than or equal to 0. For the irritation evaluation, the OGD also considers other clinically relevant data including the number of applications that reach a maximal irritation score and the number of subjects that discontinue the product applications because of unacceptable irritation.

   The same mean cumulative score could be reached with a small number of high scores (e.g., ≥ 3) as with a larger number of low scores (e.g., 1, which are of little clinical significance). Thus, it is difficult to determine the clinical meaningfulness of a given cumulative score or a given difference between products with regard to mean cumulative scores. Therefore, in addition to cumulative scores, it is necessary to also evaluate the proportion of subjects with a meaningful degree of irritation for each product. The proportion of subjects with a meaningful degree of irritation should be no higher for the test product than for the RLD, and irritation should not occur earlier in the application period for the test product than for the RLD. To be approved, the test product must be non-inferior with regard to cumulative irritation scores and also show no meaningful difference with regard to degree of irritation.

Sensitization Data Tables and Analyses

29. Please provide a frequency table showing the number of applications of each test article during the Challenge Phase with a specific combined “Dermal Response” numerical score and “Other Effect” letter score by each evaluation time point.

30. For all subjects with at least one combined score of 2 or more at 48 or 72 hours after patch removal in the Challenge Phase, please provide a table showing the actual scores for each subject at each evaluation time point during the Induction and Challenge Phases.

31. The Analysis Populations should be defined separately for each parameter and should be defined per patch instead of per subject. The Per Protocol (PP) Population evaluation of sensitization should be defined as follows:
Sensitization Analysis – includes all test articles worn (without any period of detachment longer than 24 hours) for the full 21 day induction phase AND the entire 48-hour challenge phase AND the subject must return for at least one of the scheduled evaluations at 48 and 72 hours after removal of the challenge patch. If a test article is removed prior to the end of the 48-hour challenge phase due to an intolerable reaction, the application site should be evaluated at 24, 48, and 72 hours after patch removal and be included in the sensitization analysis using LOCF.

32. For each test article, individually evaluate each PP subject with a combined score of 2 or greater at 48 or 72 hours after patch removal during the Challenge Phase for potential sensitization. A narrative description of each reaction in the challenge phase should be provided, together with the opinion of the investigator as to whether such reactions are felt to be indicative of a contact sensitization. Consider a subject to be potentially sensitized if all of the following criteria are met:

a. The subject has at least one evaluation occurring at more than 24 hours (e.g., at 48 or 72 hours) after the removal of the Challenge Phase patch.
b. The subject has a combined “Dermal Response” and “Other Effects” numeric score of at least 2 at their last evaluation during the Challenge Phase.
c. The combined “Dermal Response” and “Other Effects” numeric scores obtained during the Challenge Phase evaluations are generally higher than the combined “Dermal Response” and “Other Effects” numeric scores obtained during the Induction Phase.
d. If the subject completed a Rechallenge Phase, the above 3 criteria were met during both the Challenge Phase and the Rechallenge Phase.

Scores that resolve before 48 hours are generally considered to be due to irritation instead of sensitization. Provide the total number of subjects considered sensitized to the test product and RLD.

33. The sponsor should provide descriptive statistics comparing the proportion of subjects sensitized or potentially sensitized to each test article.

Adhesion Data Tables and Analyses

34. Please provide a frequency table showing the number of patches with each adhesion score at each evaluation time point during the first application of the test product and RLD. Also provide the number of patches that are completely detached at each evaluation time point for the test product and RLD. If a patch is completely detached, provide the time from patch application to complete detachment (i.e., duration of patch wear) for the test product and RLD. If a patch is reinforced, provide the time from patch application to reinforcement for the test product and RLD.

35. The Analysis Populations should be defined separately for each parameter and should be defined per patch instead of per subject. The Per Protocol (PP) Population evaluation for adhesion should be defined as follows:

Adhesion Analysis – should include all patches except those removed early for unacceptable irritation or those that dropped out of the study before the end of the first 24-hour application.

36. The adhesion score and the time from application until patch detachment (i.e., duration of patch wear) should be evaluated for the first application of the test product and RLD, and a statistical analysis of the comparative results should be performed.
The adhesion evaluation of the active test product and RLD must demonstrate that the upper bound of the one-sided 95% CI of the mean adhesion score for the test product minus 1.25 times the mean adhesion score for the RLD must be less than or equal to 0. For the adhesion evaluation, OGD also considers the number of subjects that experience detachment or unacceptable adhesion scores and how early in the application period those unacceptable scores are observed.

The same mean score could be reached with a small number of high scores (e.g., \( \geq 3 \)) as with a larger number of low scores (e.g., 1, which are of little clinical significance). Thus, it is difficult to determine the clinical meaningfulness of a given mean score or a given difference between products with regard to mean scores. Therefore, in addition to mean scores, it is necessary to also evaluate the proportion of subjects with a meaningful degree of detachment for each product. The proportion of subjects with a meaningful degree of detachment should be no higher for the test product than for the RLD, and detachment should not occur earlier in the application period for the test than for the RLD. To be approved, the test product must be non-inferior with regard to mean adhesion scores and also show no meaningful difference with regard to degree of detachment.

**Data Submission**

37. Study data should be submitted to the OGD in electronic format.

a. A list of file names included in the CD or diskette(s), with a simple description of the content of each file, should be included.

b. Please provide a “pdf” document with a detailed description of the codes that are used for each variable in each of the SAS datasets (for example, Y=yes, N=no for analysis population).

c. All SAS transport files should include .xpt as the file extension and should not be compressed. A simple SAS program to open the data transport files and SAS files should be included.

d. Primary data sets should consist of two data sets: No Last-Observation-Carried-Forward (NO LOCF-pure data set) and Last-Observation-Carried-Forward (LOCF-modified data set).

e. Please provide a separate dataset for each study to include such variables as demographics, baseline admission criteria, baseline vital signs, adverse events, reasons for discontinuation of treatment, concomitant medications, medical history, compliance and comments, etc.

38. Please provide a summary dataset containing a separate line listing for each test article per subject (if data exist) using the following headings, if applicable:

a. Study identifier

b. Subject identifier

c. Site identifier: study center

d. Age

e. Age units (years)

f. Sex

g. Race

h. Name of Actual Treatment (exposure): test article (i.e., test product, RLD, optional vehicle patch and optional negative control)

i. Location of Dose Administration: patch application site

j. Duration of Treatment (total exposure in days) during Induction Phase: time from first application to discontinuation of test article during Induction Phase

k. Duration of Treatment (total exposure in days) during Challenge Phase: time from first application to discontinuation of test article during Challenge Phase
1. Per Protocol (PP) population inclusion for irritation analysis (yes/no)
2. Reason for exclusion from PP population for irritation analysis
3. PP population inclusion for sensitization analysis (yes/no)
4. Reason for exclusion from PP population for sensitization analysis
5. PP population inclusion for adhesion analysis (yes/no)
6. Reason for exclusion from PP population for adhesion analysis
7. Test article moved (yes/no)
8. Number of times test article moved
9. Test article discontinued (yes/no)
10. Reason for test article discontinuation
11. Adverse event(s) reported for this treatment arm (yes/no)

Please refer to Table 2 as an example. This sample table may contain additional information not applicable to your study and/or it may not contain all information applicable to your study.

**Table 2: Example of a summary dataset for each individual test article per subject**

<table>
<thead>
<tr>
<th>STUDYID</th>
<th>SUBJID</th>
<th>SITEID</th>
<th>AGE</th>
<th>AGEU</th>
<th>SEX</th>
<th>RACE</th>
<th>EXTRT</th>
<th>EXLOC</th>
<th>EXDURind</th>
<th>EXDURch</th>
<th>ppirr</th>
<th>ppirr_rs</th>
<th>ppsen</th>
<th>ppsen_rs</th>
<th>ppadh</th>
<th>ppadh_rs</th>
<th>mv</th>
<th>mv_n</th>
<th>dis</th>
<th>dis_rs</th>
<th>AErpt</th>
</tr>
</thead>
<tbody>
<tr>
<td>101</td>
<td>1</td>
<td>01</td>
<td>54</td>
<td>YEARS</td>
<td>M</td>
<td>1</td>
<td>RUA</td>
<td>21</td>
<td>2</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>1</td>
<td>01</td>
<td>54</td>
<td>YEARS</td>
<td>M</td>
<td>1</td>
<td>LUA</td>
<td>21</td>
<td>2</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>2</td>
<td>01</td>
<td>45</td>
<td>YEARS</td>
<td>M</td>
<td>2</td>
<td>RUA</td>
<td>21</td>
<td>2</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>2</td>
<td>01</td>
<td>45</td>
<td>YEARS</td>
<td>M</td>
<td>2</td>
<td>LUA</td>
<td>21</td>
<td>2</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Capitalized headings are from Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) Implementation Guide (IG) for Human Clinical Trials V3.1.2 Draft dated 7/25/07.

STUDYID: Study Identifier
SUBJID: Subject Identifier for the Study
SITEID: Study Site Identifier
AGE: Age
AGEU: Age units (years)
SEX: Sex, e.g., M, F, U for Male, Female, Unknown
RACE: Race, e.g. 1, 2, 3, 4, 5 (1=White, 2=Black or African American, 3=Asian, 4=American Indian or Alaska Native, 5=Native Hawaiian or Other Pacific Islanders)
EXTRT: Name of Actual Treatment (exposure), e.g., A=test product, B=RLD, C=optional vehicle patch, D=optional negative control
EXLOC: Location of Dose Administration (exposure): specific anatomical site of patch application, e.g., RUA=right upper arm, LUA=left upper arm
EXDURind: Duration of Treatment during Induction Phase (exposure in days; 21 days exposure planned during Induction Phase)
EXDURch: Duration of Treatment during Challenge Phase (exposure in days; 2 days exposure planned during Challenge Phase)
ppirr: Per Protocol (PP) population for irritation analysis, e.g., Y, N (Yes or No)
ppirr_rs: Reason for exclusion from PP population for irritation analysis, e.g., A=prematurely discontinued prior to completing irritation phase due to AE that was not intolerable irritation, B=failed to complete irritation phase due to lost to follow-up, C=failed to complete irritation phase due to subject moved out of the area, etc.
ppsen: PP population for sensitization analysis, e.g., Y, N (Yes or No)
ppsen_rs: Reason for exclusion from PP population for sensitization analysis, e.g., A=prematurely discontinued prior to completing challenge phase due to AE that was not intolerable irritation, B=failed to return for at least one of the two challenge visits at 48 and 72 hours, etc.
ppadh: Per Protocol (PP) population for adhesion analysis, e.g., Y, N (Yes or No)
ppadh_rs: Reason for exclusion from PP population for adhesion analysis, e.g., A=prematurely discontinued prior to completing Day 8 adhesion scoring due to AE that was not intolerable irritation, B=failed to complete Day 8 adhesion scoring due to lost to follow-up, C=failed to complete Day 8 adhesion scoring due to subject moved out of the area, etc.
mv: Test article moved, e.g., Y, N (Yes or No)
mv_n: Number of times test article was moved, e.g., 1, 2, 3, etc.
dis: Discontinuation of the test article, e.g., Y, N (Yes or No)
dis_rs: Reason for test article discontinuation, e.g., A=irritation, etc.
AErpt: Adverse event(s) reported for this treatment arm, e.g., Y, N (Yes or No)

39. For the Irritation, Sensitization and Adhesion Analyses, please provide a separate line listing for each individual test article per subject, per each visit (if data exist) using the following headers, if applicable:

a. Subject identifier
b. Treatment: test article (i.e., test product, RLD, optional vehicle patch and optional negative control)
c. Application Sequence: number of particular test article application (i.e., 1=first, 2=second, 3=third)
d. Location of Dose Administration: test article application site
e. Visit number
f. Visit date
g. Number of days since baseline visit
h. Application day of week (i.e., Sunday, Monday, Tuesday, etc.)
i. Application date and time
j. Date and time of removal or complete detachment
k. Duration of Treatment: time (hours) from individual test article application to removal or complete detachment
l. Reason for exclusion of data from this individual test article from analysis
m. Scoring date
n. Adhesion scores (e.g., Days 2-8)
o. Induction “Dermal Response” numeric score for each site
p. Induction “Other Effects” letter score for each site
q. Challenge “Dermal Response” numeric score for each site
r. Challenge “Other Effects” letter score for each site
s. Potentially sensitized (yes/no)
t. Identity of the evaluator
u. Was the individual test article reinforced with tape or overlay (yes/no)
v. If individual test article was reinforced, time from individual test article application to reinforcement
w. Individual test article moved (yes/no)
x. Number of times individual test article moved
y. Date of each move of individual test article
z. Individual test article discontinued (yes/no)
aa. Reason for discontinuation
bb. Date individual test article discontinued
cc. Adverse event reported during this visit (yes/no)

Please refer to Table 3 as an example. This sample table may contain additional information not applicable to your study and/or it may not contain all information applicable to your study.

**Table 3: Example of dataset containing one line listing for each individual test article per visit per subject**

<table>
<thead>
<tr>
<th>SUBJID</th>
<th>EXRTT</th>
<th>EXSEQ</th>
<th>EXLOC</th>
<th>VISITNUM</th>
<th>SVSTDTC</th>
<th>ELTMBL</th>
<th>day_wk</th>
<th>itaSTDTC</th>
<th>itaENDTC</th>
<th>itaDUR</th>
<th>exc_rs</th>
<th>ser_date</th>
<th>adh_2</th>
<th>adh_3</th>
<th>ind_n1</th>
<th>ind_c1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A</td>
<td>1</td>
<td>RUA</td>
<td>1</td>
<td>2004-07-01</td>
<td>1</td>
<td>Monday</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Capitalized headings are from Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) Implementation Guide (IG) for Human Clinical Trials V3.1.2 Draft dated 7/25/07.

- **SUBJID:** Subject Identifier for the Study
- **EXRTT:** Name of Actual Treatment (exposure), e.g. A=test product, B=RLD, C= optional vehicle patch, D=optional negative control
- **EXSEQ:** Sequence Number of exposure to particular test article (e.g. application number 1, 2, 3, etc.)
- **EXLOC:** Location of Dose Administration (exposure): specific anatomical site of patch application, e.g., RUA=right upper arm, LUA=left upper arm
- **VISITNUM:** Visit Sequence Number
- **SVSTDTC:** Visit date: (SVSTDTC=Subject Visit Start Date Time-Character)
- **ELTMBL:** Elapsed Time since Baseline (days)
day_wk: Day of week of individual test article application (i.e., Sunday, Monday, Tuesday, etc.)
itaSTDTC: Individual test article application date and time: start date/time of individual test article
itaENDTC: Individual test article removal date and time: end date/time of individual test article
itaDUR: Individual test article exposure duration (hours) (i.e., time from individual test article application to removal)
exc_rs: Reason for exclusion of data from this individual test article from analysis, e.g., A=subject did not show for appointment, B=test article detached for more than 24 hours, C=protocol/exclusion criteria violation, etc.
scr_date: Scoring date
adh_2: Adhesion score for Day 2
adh_3: Adhesion score for Day 3 (etc. to Day 8)
ind_n1: Numeric “Dermal Response” score for the first site during Induction
ind_c1: Character “Other Effects” score for the first site during Induction
ind_n2: Numeric “Dermal Response” score for the second site (if application site moved due to excessive irritation) during Induction
ind_c2: Character “Other Effects” score for the second site during Induction
ind_n3: Numeric “Dermal Response” score for the third site during Induction
ind_c3: Character “Other Effects” score for the third site during Induction
ch_n1: Numeric “Dermal Response” score for the Challenge site
ch_c1: Character “Other Effects” score for the Challenge site
potsens: Potentially sensitized
EVAL: Evaluator: identity of the evaluator
reinf: Individual test article reinforced with tape or overlay (yes/no)
reinf_tm: If individual test article was reinforced, time (hours) from individual test article application to reinforcement
mv: Individual test article moved, e.g., Y, N (Yes or No)
mv_n: Number of times individual test article was moved, e.g., 1, 2, etc.
mv_dt1: Date of first move of individual test article
mv_dt2: Date of second move of individual test article
mv_dt3: Date of third move of individual test article
dis: Discontinuation of the individual test article, e.g., Y, N (Yes or No)
dis_rs: Reason for individual test article discontinuation, e.g., A=irritation, etc.
dis_dt: Date individual test article discontinued
AErpt: Adverse Event reported during this visit, e.g., Y, N (Yes or No)

40. Please note that the guidance provided here supersedes information provided in the *Guidance for Industry: Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products*, which has been withdrawn. The information given here is general in nature and represents the current thinking of the OGD for this product and may not be appropriate for other transdermal products.

41. Sponsors may submit the protocol for review and comment prior to conducting the study.